Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer

In conclusion, regimen 3 was well tolerated by patients with pre-treated biliary tract or pancreatic cancer.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research